Adipotide

Adipotide is a chimeric peptidomimetic — two functional domains stitched together by a Gly-Gly linker. The first domain (CKGGRAKDC) is a homing motif that recognises a receptor complex found almost exclusively on the capillaries feeding white adipose tissue. The second domain, D-(KLAKLAK)₂, is a pro-apoptotic warhead that destroys mitochondria once it gets inside a cell. The mechanism is therefore ligand-directed vascular pruning: adipotide doesn't mobilise fat, suppress appetite, or accelerate lipolysis. It kills the blood supply feeding the fat depot, and the adipocytes involute for lack of perfusion.

Vascular Homing via the Prohibitin–ANXA2 Complex#

Adipotide was identified through phage-display vascular mapping, which flagged prohibitin (PHB) as differentially expressed on WAT endothelium relative to endothelium elsewhere in the body. The CKGGRAKDC homing sequence binds a surface PHB–annexin A2 (ANXA2) heterocomplex enriched on the capillaries irrigating white fat. This is what gives the molecule its tissue selectivity — the warhead alone would be indiscriminately cytotoxic, but the homing domain concentrates delivery at adipose vasculature.

"A synthetic peptide targeting adipose vasculature induced selective apoptosis of endothelial cells, leading to rapid depletion of white adipose tissue in obese mice, without affecting other tissue types." — Kolonin MG et al., Nature Medicine, 2004

Practical consequence: activity scales with available target. Lean subjects have less WAT vasculature to prune and therefore respond less — a feature that caps the compound's utility in already-lean physique users and explains the flat response reported in leaner community logs.

Mitochondrial Disruption by D-(KLAKLAK)₂#

Once bound and internalised, the D-amino-acid (KLAKLAK)₂ segment — an amphipathic α-helix resistant to proteolysis thanks to its D-stereochemistry — inserts into the inner mitochondrial membrane, collapses the membrane potential, and triggers caspase-dependent apoptosis of the targeted endothelial cell. Capillaries die, the downstream adipocyte depot loses perfusion, and the fat mass is reabsorbed over the following weeks.

This is why the fat loss lags the dosing window: body-weight curves in the primate data kept declining for roughly three weeks after the last injection, as ischemic involution played out.

Secondary Effect on Fatty-Acid Uptake#

The PHB–ANXA2 complex isn't just a docking site — it also scaffolds CD36-mediated fatty-acid transport into adipocytes. Disrupting the complex reduces lipid influx into remaining depots, adding a second, non-apoptotic contribution to the overall fat-loss signal.

"These results show that the prohibitin–ANXA2 complex regulates fatty acid uptake in adipose tissue and functions as the vascular target for adipotide." — Salameh A et al., JCI Insight, 2016

This likely explains why insulin sensitivity improves before the bulk of the mass loss has occurred: reduced ectopic lipid loading and WAT inflammation precede the final body-composition change.

Metabolic Reprogramming of Residual WAT#

Beyond raw mass loss, the primate data show that the remaining adipose tissue behaves differently post-cycle — lower inflammatory tone, reduced serum triglycerides and free fatty acids, and markedly improved whole-body insulin action.

"Adipotide caused up to an 11% reduction in body weight and significant improvements in insulin resistance, while lean monkeys exhibited no change in weight." — Barnhart KF et al., Science Translational Medicine, 2011

In the same rhesus cohort, obese subjects lost roughly 39% of total fat mass and doubled insulin sensitivity across a 28-day protocol — a metabolic shift that cannot be explained by mass loss alone and points to genuine reprogramming of residual WAT.

Adiposity-Dependent, Not Depot-Selective#

A persistent community misconception is that adipotide performs "spot reduction" at stubborn depots. The imaging data don't support this. The MRI and DEXA readouts from the primate work showed proportionate loss across visceral and subcutaneous compartments, scaling with the local density of PHB-positive vasculature rather than with any specific anatomic site. Users chasing a particular depot will see reduction there only in proportion to its share of total WAT — which, for visceral fat, is actually favourable, since visceral depots are densely vascularised.

The Renal Tradeoff Is Mechanistic, Not Incidental#

The kidney is the clearance organ, and the proximal tubule concentrates the peptide during reabsorption. This is why the dose-limiting toxicity is renal, not hepatic or cardiac — it's a direct consequence of how the molecule is eliminated, not an off-target surprise. Hydration, avoidance of concurrent nephrotoxins, and mid-cycle renal bloodwork are therefore not optional add-ons; they are built into the mechanism itself.

Common (most users)#

• Injection-site reactions — mild erythema, bruising, or tenderness at the SC site. Rotate across quadrants of the abdominal fat pad; avoid reusing a site within 72 hours. Ice the site post-injection if tender.
• Transient appetite reduction — onset typically day 5–10, welcome for a cut but worth tracking. Maintain protein intake (≥1g/lb lean mass) and electrolytes even when caloric intake drops.
• Mild thirst / increased urination — expected given renal clearance. Baseline hydration of 3–4 L/day is non-negotiable; add electrolytes (sodium, potassium, magnesium) rather than plain water alone.
• Low-grade fatigue in week 1 — usually resolves as the body adapts. If it persists past day 10, it's a prompt to check a mid-cycle renal panel rather than push through.

Uncommon (dose-dependent or individual)#

• Rising serum creatinine / falling eGFR — the signature dose-limiting signal. Any rise above baseline at the mid-cycle draw is reason to hold the dose; a 20%+ rise is reason to stop. Cystatin C picks this up earlier than creatinine and should be on the panel.
• Microalbuminuria / new proteinuria — earliest tubular-stress marker and the reason urinalysis is part of the baseline and mid-cycle workup. New proteinuria ends the cycle.
• Electrolyte shifts — sodium and potassium disturbances secondary to tubular dysfunction. Caught on the same CMP that tracks creatinine.
• Menstrual irregularity — reported anecdotally in female subjects, mechanistically consistent with prohibitin expression on ovarian vasculature. Grounds to discontinue and defer future cycles.
• Additive appetite suppression when stacked on GLP-1s — not harmful in itself but can drive unintentional under-eating. Track intake; maintain protein floor.

"Adipotide caused up to an 11% reduction in body weight and significant improvements in insulin resistance, while lean monkeys exhibited no change in weight." — Barnhart et al., Science Translational Medicine (2011)

The lean-subject null result is the other side of the efficacy story: leaner users have less WAT vascular target, so less systemic exposure of the homing peptide to productive binding sites — and proportionally more to spill into renal clearance. Leaner physique-focused users should start at the low end (0.25 mg/kg) and treat the renal signal as the ceiling, not the dose.

Rare but serious#

• Acute kidney injury with incomplete recovery — the Barnhart primate data described renal effects as dose-dependent and reversible, but those were 28-day observations. Independent reports in the community describe cases where renal markers did not fully normalize at the 90-day post-cycle check. Warning signs: creatinine rise >30% from baseline, new significant proteinuria, oliguria, or flank pain. Stop immediately; do not attempt another cycle.
• Dehydration-driven prerenal injury — the interaction between cutting-phase caloric and fluid restriction and a renally-cleared peptide is the most preventable serious adverse event. A cutting diet without electrolyte management is not the context to run adipotide.
• Off-target vascular effects — prohibitin is expressed beyond WAT endothelium (bone marrow, ovarian, and some tumor vasculature). No clinical case series documents this in humans, but any unexplained cytopenia, reproductive symptom, or new mass during or after a cycle warrants workup rather than a wait-and-see.

"A synthetic peptide targeting adipose vasculature induced selective apoptosis of endothelial cells, leading to rapid depletion of white adipose tissue in obese mice, without affecting other tissue types." — Kolonin et al., Nature Medicine (2004)

The selectivity holds in animal models at documented doses. It is not a license to freelance on dose or duration.

Hard contraindications#

• Pre-existing renal impairment — any baseline eGFR <90, known CKD, single kidney, or history of nephropathy. The kidney is both the clearance organ and the dose-limiting toxicity target; there is no safe adipotide protocol for a compromised renal baseline.
• Baseline proteinuria — closes the door on adipotide entirely.
• Concurrent nephrotoxic agents — NSAIDs (including daily low-dose), aminoglycosides, cisplatin-class chemotherapeutics, high-dose IV contrast within the cycle window. Swap NSAIDs to acetaminophen for the duration.
• Active malignancy — prohibitin expression on some tumor vasculature makes the effect unpredictable; not a compound to run while a cancer workup or treatment is active.
• Pregnancy or attempted conception — the peptide induces endothelial apoptosis; there is zero reproductive-safety data.
• Dehydration states — aggressive water-cuts, contest prep peak-week protocols, endurance events in heat. Run adipotide in a well-hydrated metabolic phase or not at all.
• Concurrent heavy oral AAS cycle — the combined renal and hepatic load is not worth it. Schedule adipotide into a non-cycle window or a bridge.

Gender-specific considerations and PCT#

Adipotide has no interaction with the HPG axis, no androgen-receptor activity, no aromatase effect. PCT is not required. No hormonal ancillaries apply.

Female subjects face one additional consideration: prohibitin expression on ovarian vasculature raises a theoretical concern for follicular or menstrual disruption, and anecdotal community reports echo this. Female users with active fertility plans should defer entirely. Female users without fertility plans should still treat any menstrual change during or after a cycle as a signal to discontinue and defer future exposure until a full workup clears it.

The final framing: adipotide's side-effect profile is dominated by one organ system. Get the renal baseline right, hydrate aggressively, check the mid-cycle panel, and stop on any signal — and the compound behaves. Skip the monitoring and it is one of the more dangerous peptides on the research market.